Dr. Stuart Mair, Global Vice President, Medical, Early Development, has contributed to a scientific article on Arthritis Research & Therapy.

Background
Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates the stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibitor under development for the treatment of ankylosing spondylitis (AS) and other inflammatory diseases. As part of a phase I clinical trial to assess safety and tolerability, we evaluated target engagement, pharmacokinetics, and pharmacodynamics of CC-99677.

Methods
The MK2 inhibitor CC-99677 was evaluated for its effect on cytokine expression in vitro in peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with a definitive AS diagnosis. A novel in vitro model was developed to compare the potential for tachyphylaxis of CC-99677 and p38 inhibitors in THP-1 cells. The effect of CC-99677 on tristetraprolin (TTP) and cytokine mRNA was assessed in stimulated human monocyte-derived macrophages. In a first-in-human study, thirty-seven healthy volunteers were randomly assigned to daily oral doses of CC-99677 or placebo, and blood was collected at pre-specified time points before and after dosing. CC-99677 concentrations were assessed in the plasma, and CC-99677 binding to MK2 was evaluated in PBMCs. Ex vivo stimulation of the whole blood was conducted by participants in the first-in-human study to assess the pharmacodynamic effects.

Results
In vitro, CC-99677 inhibited tumor necrosis factor (TNF), interleukin (IL)-6, and IL-17 protein production in samples of monocytes and macrophages from AS patients and healthy volunteers via an mRNA-destabilization mechanism. In the in vitro model of tachyphylaxis, CC-99677 showed a differentiated pattern of sustained TNF protein inhibition compared with p38 inhibitors. CC-99677 reduced TTP phosphorylation and accelerated the decay of inflammatory cytokine mRNA in lipopolysaccharide-stimulated macrophages. Administration of CC-99677 to healthy volunteers was safe and well-tolerated, with linear pharmacokinetics and sustained reduction of ex vivo whole blood TNF, IL-6, and chemokine synthesis.

Conclusions
CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases and may overcome the limitations of p38 MAPK inhibition.

Gaur, R., Mensah, K.A., Stricker, J. et al. CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production. Arthritis Res Ther 24, 199 (2022)/

Download Quotient Sciences' peer-reviewed resource, 'Controlled synthesis of SPION@SiO2 nanoparticles using design of experiments', published in Materials Advances.

Quotient Sciences, in collaboration with KU Leuven and academic partners, contributed to a comprehensive industry survey published in the International Journal of Pharmaceutics, examining current practices in pediatric oral drug product development. 

The study assessed how EU and US pediatric drug product development regulations have influenced formulation strategies, with a focus on the integration of in vitro, in silico, and clinical tools.

Findings revealed that while regulatory frameworks have driven progress, challenges remain in developing age-appropriate formulations, particularly for neonates and infants. The survey highlighted variability in the application of physiologically based pharmacokinetic (PBPK) modeling, biopharmaceutics, and predictive dissolution testing, underscoring the need for harmonized methodologies and improved data sharing across the industry.

This research supports the advancement of pediatric drug development by identifying key gaps and promoting the use of model-informed drug development (MIDD) approaches to optimize formulation design and regulatory alignment.

Download the resource to read more about the program.

Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating the mass balance recovery and disposition of AZD4831 in humans. Download our publication here.

MK-X had demonstrated poor colonic absorption in dogs and conventional matrix-based controlled release formulations failed to achieve adequate trough concentrations in a human pharmacokinetic (PK) study to support once-daily dosing.

Download Quotient Sciences', 'Rapid Formulation Development & Clinical Testing of Gastro-Retentive Controlled Release Tech to Enable Once-Daily Dosing'.

Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers. Download our scientific poster titled, 'Clinical Pharmacokinetics and Pharmacodynamics of ME-401' from AACR 2016.

A randomized double-blind dose escalation study to evaluate the safety and dose-response of subcutaneous administration of coversin in healthy subjects.

Download a copy of our scientific poster from ASCPT 2016 titled, 'A randomized double-blind dose escalation study of coversin'.

When administered orally, peptide-based drugs are susceptible to degradation in the stomach due to exposure to low pH and proteolytic enzymes. 

Download our poster from ADA 2017 titled, 'A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide'.

Absorption of oral peptide-based drug formulations is challenged by the fact that peptides are degraded in the stomach due to low pH and proteolytic enzymes, as well as by their limited permeability across the gastrointestinal epithelium.

Download our scientific poster entitled, 'Site of absorption of an oral formulation of semaglutide' from ADA 2017.

Maximizing the Potential of Amorphous Spray-Dried Dispersions to Enhance Clinical Bioavailability. Amorphous Dispersions (ADs) provide an effective approach to oral bioavailability improvement for poorly soluble compounds.